

TRADEMARK ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

ETAS ID: TM368500

SUBMISSION TYPE:	NEW ASSIGNMENT		
NATURE OF CONVEYANCE:	Security Agreement		
CONVEYING PARTY DATA			
Name	Formerly	Execution Date	Entity Type
Bakotic Pathology Associates, L.L.C.		01/07/2016	LIMITED LIABILITY COMPANY: GEORGIA
RECEIVING PARTY DATA			
Name:	BMO Harris Bank N.A., as Agent		
Street Address:	111 West Monroe Street		
City:	Chicago		
State/Country:	ILLINOIS		
Postal Code:	60603		
Entity Type:	Association: UNITED STATES		
PROPERTY NUMBERS Total: 2			
Property Type	Number	Word Mark	
Registration Number:	4163739	BAKO	
Registration Number:	4163730	WE ARE PODIATRIC PATHOLOGY	
CORRESPONDENCE DATA			
Fax Number:			
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>			
Email:	marina.kelly@thomsonreuters.com		
Correspondent Name:	Gregory T. Pealer		
Address Line 1:	111 West Monroe Street		
Address Line 2:	Chapman and Cutler LLP		
Address Line 4:	Chicago, ILLINOIS 60603		
NAME OF SUBMITTER:	Gregory T. Pealer		
SIGNATURE:	/Marina Kelly, Thomson Reuters/		
DATE SIGNED:	01/08/2016		
Total Attachments: 7			
source=7 updated Trademark Security Agreement#page1.tif			
source=7 updated Trademark Security Agreement#page2.tif			
source=7 updated Trademark Security Agreement#page3.tif			
source=7 updated Trademark Security Agreement#page4.tif			

OP \$65.00 4163739

source=7 updated Trademark Security Agreement#page5.tif
source=7 updated Trademark Security Agreement#page6.tif
source=7 updated Trademark Security Agreement#page7.tif

TRADEMARK SECURITY AGREEMENT

This TRADEMARK SECURITY AGREEMENT, dated as of January 7, 2016, is made by each of the entities listed on the signature pages hereof (each a “Grantor” and, collectively, the “Grantors”), in favor of BMO Harris Bank N.A. (“BMO”), as administrative agent (in such capacity, together with its successors and permitted assigns, the “Agent”) for the Lenders and the L/C Issuers (as defined in the Credit Agreement referred to below) and the other Secured Parties.

WITNESSETH:

WHEREAS, pursuant to the Credit Agreement, dated as of January 7, 2016 (as the same may be amended, restated, amended and restated, supplemented or otherwise modified from time to time, the “Credit Agreement”), by and among BPA Merger Corp., a Delaware corporation (which, immediately upon the consummation of the Closing Date Merger (as defined in the Credit Agreement), was merged with and into BPA Holding Corp., a Delaware corporation (the “Company”), with the Company surviving such merger as the Borrower thereunder), the other Credit Parties from time to time party thereto, the Lenders and the L/C Issuers from time to time party thereto and BMO, as Agent for the Lenders and the L/C Issuers, the Lenders and the L/C Issuers have severally agreed to make extensions of credit to the Borrower upon the terms and subject to the conditions set forth therein;

WHEREAS, each Grantor (other than the Borrower) has agreed, pursuant to a Guaranty and Security Agreement of even date with the Credit Agreement in favor of the Agent (as the same may be amended, restated, amended and restated, supplemented or otherwise modified from time to time, the “Guaranty and Security Agreement”), to guarantee the Obligations (as defined in the Credit Agreement) of the Borrower; and

WHEREAS, all of the Grantors are party to the Guaranty and Security Agreement pursuant to which the Grantors are required to execute and deliver this Trademark Security Agreement;

NOW, THEREFORE, in consideration of the premises and to induce the Lenders, the L/C Issuers and the Agent to enter into the Credit Agreement and to induce the Lenders and the L/C Issuers to make their respective extensions of credit to the Borrower thereunder, each Grantor hereby agrees with the Agent as follows:

SECTION 1. DEFINED TERMS.

Capitalized terms used herein without definition are used as defined in the Guaranty and Security Agreement.

SECTION 2. GRANT OF SECURITY INTEREST IN TRADEMARK COLLATERAL.

Each Grantor, as collateral security for the prompt and complete payment and performance when due (whether at stated maturity, by acceleration or otherwise) of the Secured Obligations of such Grantor, hereby pledges to the Agent for the benefit of the Secured Parties,

and grants to the Agent for the benefit of the Secured Parties a Lien on and security interest in, all of its right, title and interest in, to and under the following Collateral of such Grantor, but excluding all Excluded Property (the “*Trademark Collateral*”):

(a) all of its Trademarks (as defined in the Credit Agreement) (but excluding any intent-to-use trademark application prior to the filing and acceptance of a “Statement of Use” or “Amendment to Alleged Use” with respect thereto), including, without limitation, those referred to on Schedule 1 hereto;

(b) all renewals and extensions of the foregoing;

(c) all goodwill of the business connected with the use of, and symbolized by, each such Trademark; and

(d) all income, royalties, proceeds and Liabilities at any time due or payable or asserted under and with respect to any of the foregoing, including, without limitation, all rights to sue and recover at law or in equity for any past, present and future infringement, misappropriation, dilution, violation or other impairment thereof.

SECTION 3. GUARANTY AND SECURITY AGREEMENT.

The security interest granted pursuant to this Trademark Security Agreement is granted in conjunction with the security interest granted to the Agent pursuant to the Guaranty and Security Agreement and each Grantor hereby acknowledges and agrees that the rights and remedies of the Agent with respect to the security interest in the Trademark Collateral made and granted hereby are more fully set forth in the Guaranty and Security Agreement, the terms and provisions of which are incorporated by reference herein as if fully set forth herein. In the event of any conflict between this Agreement and the Guaranty and Security Agreement, the Guaranty and Security Agreement shall control.

SECTION 4. GRANTOR REMAINS LIABLE.

Each Grantor hereby agrees that, anything herein to the contrary notwithstanding, but subject to the terms of the Guaranty and Security Agreement, such Grantor shall assume full and complete responsibility for the prosecution, defense, enforcement or any other necessary or desirable actions in connection with their Trademarks subject to a security interest hereunder.

SECTION 5. TERMINATION.

This Trademark Security Agreement shall terminate and the Lien on the security interest in the Trademark Collateral shall be released upon the payment and performance of the Secured Obligations (other than any outstanding indemnification obligations) and cash collateralization of Letters of Credit. Upon the termination of this Trademark Security Agreement, the Agent shall execute all documents, make all filings, and take all other actions reasonably requested by the

Grantors to evidence and record the release of the Lien on and security interests in the Trademark Collateral granted herein.

SECTION 6. COUNTERPARTS.

This Trademark Security Agreement may be executed in any number of counterparts and by different parties in separate counterparts, each of which when so executed shall be deemed to be an original and all of which taken together shall constitute one and the same agreement. Signature pages may be detached from multiple separate counterparts and attached to a single counterpart. Delivery of an executed signature page of this Trademark Security Agreement by facsimile transmission or Electronic Transmission shall be as effective as delivery of a manually executed counterpart hereof.

SECTION 7. GOVERNING LAW.

The laws of the State of New York shall govern all matters arising out of, in connection with or relating to this Trademark Security Agreement, including, its validity, interpretation, construction, performance and enforcement (including, any claims sounding in contract or tort law arising out of the subject matter hereof and any determinations with respect to post-judgment interest).

[REMAINDER OF PAGE INTENTIONALLY LEFT BLANK; SIGNATURE PAGE FOLLOWS]

IN WITNESS WHEREOF, each Grantor has caused this Trademark Security Agreement to be executed and delivered by its duly authorized officer as of the date first set forth above.

Very truly yours,

BAKOTIC PATHOLOGY ASSOCIATES, L.L.C., as
Grantor

By: 
Name: Scott Bakotic
Title: Chief Financial Officer


PODCEUTICALS L.L.C., as Grantor

By: 
Name: Scott Bakotic
Title: Chief Financial Officer

[Signature Page to Trademark Security Agreement]

Acknowledged and Agreed as of the
date first above written:

BMO HARRIS BANK N.A., as Agent

By:  _____

Name: Adam Lively

Title: Managing Director

**SCHEDULE I
TO
TRADEMARK SECURITY AGREEMENT**

REGISTERED TRADEMARKS OF BAKOTIC PATHOLOGY ASSOCIATES, L.L.C.

<u>Trademark Name</u>	<u>Registration #</u>	<u>Registration Date</u>	<u>Registered Owner</u>
Bako	4,163,739	06/26/12	Bakotic Pathology Associates, L.L.C.
We ARE Podiatric Pathology	4,163,730	06/26/12	Bakotic Pathology Associates, L.L.C.

REGISTERED TRADEMARKS OF PODCEUTICALS L.L.C.

<u>Trademark Name</u>	<u>Registration #</u>	<u>Registration Date</u>	<u>Registered Owner</u>
Clinical Therapeutic Solutions	4,284,146	01/29/13	Clinical Therapeutic Solutions
CLARUS Antifungal Solution	4,310,249	03/26/13	Clinical Therapeutic Solutions
CLARUS Antifungal Solution	4,310,252	03/26/13	Clinical Therapeutic Solutions
CLARUS Antifungal Cream	4,310,248	03/26/13	Clinical Therapeutic Solutions
CLARUS Antimicrobial Shoe Spray	4,832,750	10/13/15	Clinical Therapeutic Solutions
KERA-HC Cream	4,314,790	04/02/13	Clinical Therapeutic Solutions
KERA Nail Gel	4,354,124	06/18/13	Clinical Therapeutic Solutions
KERA-42 Cream	4,396,955	09/03/13	Clinical Therapeutic Solutions
TheraNail	4,318,896	04/09/13	Clinical Therapeutic Solutions
TRI-SOFT	4,495,785	03/11/14	Clinical Therapeutic Solutions
VerruStat	4,573,489	07/22/14	Clinical Therapeutic Solutions
LidoStat	4,573,484	07/22/14	Clinical Therapeutic Solutions
MacerRx	4,577,158	07/29/14	Clinical Therapeutic Solutions
Hydro-Cutis	4,832,778	10/13/15	Clinical Therapeutic Solutions
NeuRx-TF	4,277,157	01/15/13	Clinical Therapeutic Solutions
GRANU-L8	4,872,176	12/15/15	Clinical Therapeutic Solutions